On July 18 JSC Olainfarm organized its Investor Conference Online Webinar for investors to inform about the company’s recent developments.
During the webinar the member of the management board of JSC Olainfarm Salvis Lapiņš gave an in-depth analysis about company’s 2013 first quarter financial results and informed about sales in first half of the year. Salvis Lapiņš also gave a presentation about Silvanols Ltd. history, type of business, financial results and future prospects.
During the conference Salvis Lapiņš noted that the production volume of Silvanols Ltd. can be increased aprox. 3 times, thus allowing the company to increase its sales and reach the target – 10 million lats turnover in nearest 5 years.
Answering questions sent in by the investors, Salvis Lapiņš approved that sales of JSC Olainfarm will increase in the second half of the year.
The recorded “Olainfarm” webinar is available online:http://ej.uz/OLFJulyrec,and the presentation, demonstrated during the webinar, can be found in the previously published AS “Olainfarm” announcement: https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=565928&messageId=698818.
Olainfarm thanks all participants, who joined the webinar, and encourages everybody to follow company’s announcements to get information on the next webinar!
JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.
Information prepared by:
Member of the Board
Tel: +371 6 7013 717
Cell: +371 2 6448 873